SHANGHAI, China, April 30, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and sol...
zevor-cabtagene-autoleucel-approval
The future of CAR T-cell therapy: an analysis of its rapid growth and expansion.
Within the realm of contemporary medicine, CAR T-cell therapy emerges as an innovative and groundbreaking intervention...
zevor-cabtagene-autoleucel-approval